Global X Genomics & Biotechnology ETF Rating → Does this make you sick? (From Allegiance Gold) (Ad) Free GNOM Stock Alerts $10.84 -0.01 (-0.09%) (As of 11:57 AM ET) Add Compare Share Share RatingsStock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestSocial MediaStock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestSocial Media Global X Genomics & Biotechnology ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.GNOM Aggregate RatingModerate Buy2.64Holdings in GNOM have an aggregate rating of Moderate Buy based on 421 analyst ratings issued in the past year covering 39 companies (97.3% of the portfolio).GNOM Aggregate Price Target$16.9656.44% UpsideHigh Prediction$26.65Average Prediction$16.96Low Prediction$10.05Holdings in GNOM have an aggregate price target of $16.96 and a range of $10.05 to $26.65 covering 39 companies (97.3% of the portfolio).GNOM Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy4 Buy rating(s)Moderate Buy26 Moderate Buy rating(s)Hold9 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Global X Genomics & Biotechnology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 39 GNOM Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings8.33%NTRANatera$107.66+1.1%1 of 5 stars3.00$98.47 -8.5%15Analyst UpgradeInsider Selling5.54%MRNAModerna$138.83+4.5%4 of 5 stars2.24$126.46 -8.9%17Insider Selling4.82%AAgilent Technologies$154.55+0.2%4 of 5 stars2.59$141.29 -8.6%174.74%CRSPCRISPR Therapeutics$56.12-0.2%3 of 5 stars2.35$73.93 31.7%17Gap Up4.42%RAREUltragenyx Pharmaceutical$41.58-0.7%4 of 5 stars2.92$87.85 111.3%12Positive News4.39%TECHBio-Techne$83.52-0.3%4 of 5 stars2.82$80.50 -3.6%11Positive News4.31%SRPTSarepta Therapeutics$129.27-1.6%4 of 5 stars2.86$163.94 26.8%14Analyst Forecast3.94%QGENQiagen$45.30-0.9%4 of 5 stars2.56$50.95 12.5%93.68%MYGNMyriad Genetics$25.25-0.2%2 of 5 stars2.50$25.57 1.3%83.66%ARWRArrowhead Pharmaceuticals$24.52-1.0%4 of 5 stars2.78$51.00 108.0%9Analyst Revision3.62%RNAAvidity Biosciences$30.08+2.0%1 of 5 stars3.00$38.29 27.3%7Earnings Report3.49%BMRNBioMarin Pharmaceutical$76.50-1.4%5 of 5 stars2.57$106.11 38.7%21Analyst Downgrade3.38%ILMNIllumina$110.12-0.9%5 of 5 stars2.30$164.65 49.5%203.34%RCKTRocket Pharmaceuticals$23.04+1.9%5 of 5 stars2.89$52.13 126.2%93.33%ALNYAlnylam Pharmaceuticals$148.61-0.5%5 of 5 stars2.59$216.19 45.5%17Short Interest ↑3.30%BNTXBioNTech$91.34+0.8%1 of 5 stars2.20$111.70 22.3%10Positive News3.29%NTLAIntellia Therapeutics$26.30+0.3%4 of 5 stars2.69$66.77 153.9%132.90%BEAMBeam Therapeutics$25.11+2.0%1 of 5 stars2.38$40.18 60.0%13Gap Up2.82%VCYTVeracyte$22.52-1.6%3 of 5 stars2.60$27.50 22.1%5Positive News2.49%LEGNLegend Biotech$45.64+1.1%3 of 5 stars2.92$82.74 81.3%12Earnings Report2.39%TXG10x Genomics$25.24+0.9%5 of 5 stars2.58$48.50 92.2%12Gap Up2.01%VRTXVertex Pharmaceuticals$446.75+0.3%4 of 5 stars2.48$432.18 -3.3%25Analyst Upgrade1.82%SANASana Biotechnology$8.96+2.6%2 of 5 stars2.75$11.67 30.2%4Gap Up1.62%VIRVir Biotechnology$9.65-0.8%2 of 5 stars2.57$33.57 247.9%71.44%GILDGilead Sciences$67.690.0%5 of 5 stars2.35$83.69 23.6%171.29%RGNXREGENXBIO$16.23+1.5%4 of 5 stars2.83$38.64 138.1%12Analyst Revision1.03%CDNACareDx$15.62+0.8%2 of 5 stars2.60$16.50 5.6%5Analyst ForecastGap Down0.79%PACBPacific Biosciences of California$1.97-2.5%3 of 5 stars2.53$6.59 234.6%15Gap Up0.79%FLGTFulgent Genetics$22.09-0.1%4 of 5 stars2.00$30.00 35.8%20.79%EDITEditas Medicine$5.66+0.7%4 of 5 stars2.50$13.90 145.6%100.59%LYELLyell Immunopharma$2.61-4.7%1 of 5 stars2.50$5.50 110.7%2Gap Up0.57%ALLOAllogene Therapeutics$2.70-2.5%3 of 5 stars2.67$11.94 342.3%9Earnings ReportAnalyst Revision0.52%CRBUCaribou Biosciences$3.19-5.9%2 of 5 stars2.75$21.50 574.0%4High Trading Volume0.51%VERVVerve Therapeutics$5.99+0.2%2 of 5 stars2.75$33.00 450.9%8Gap Up0.40%QUREuniQure$4.90-2.2%2 of 5 stars2.71$24.75 405.1%7Gap Up0.39%TSVT2seventy bio$4.51-6.0%2 of 5 stars2.60$12.86 185.1%10Gap Up0.34%PSTXPoseida Therapeutics$3.32+4.1%4 of 5 stars3.00$14.67 341.8%3Analyst Revision0.20%BLUEbluebird bio$1.04+1.0%2 of 5 stars2.27$5.74 452.4%11Gap Up0.05%SCLXScilex$1.25+38.9%2 of 5 stars3.00$6.00 380.0%2Analyst RevisionGap UpHigh Trading Volume This page (NASDAQ:GNOM) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldShocking: One AI startup's revenue could surge 4,735%Manward PressDoes this make you sick?Allegiance GoldCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingBiden Nomination CANCELED?The Freeport SocietyThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global X Genomics & Biotechnology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
